Advances in the Administration of Vitamin D Analogues to Support Bone Health and Treat Chronic Diseases
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Vitamin D (VD) exerts a wide variety of biological actions in addition to its well-known roles in calcium homeostasis. Nutritional VD deficiency induces rachitic abnormalities in growing children and osteomalacia in adults, and it has been proposed to underlie the onset and development of multiple non-communicable chronic diseases. Therefore, the administration of VD or synthetic VD analogues represents a promising therapeutic strategy; indeed, VD and a VD agonist have shown clinical promise in mitigating osteoporosis and symptoms of insufficient calcium intake. However, even though high doses of VD analogues have shown pre-clinical efficacy against several diseases, including cancers, they have not yet had wide-spread clinical success. This difference may be due to limitation of clinical doses in light of the inherent calcemic action of VD. An approach to overcome this problem involves the development of VD analogues with lower calcemic activity, which could be administered in high doses to attenuate the onset and progress of disease. In a similar strategy, selective estrogen receptor modulators have had success as anti-osteoporosis drugs, and they have shown benefit for other estrogen target organs by serving as partial antagonists or agonists of estrogen receptor α. It is thus conceivable to generate synthetic partial antagonists or agonists for the VD receptor (VDR) that would exert beneficial effects on bone and other VD target organs. In this review, we discuss the molecular basis of the development of such synthetic VDR ligands from the viewpoint of roles of VDR in gene regulation.
Abstract
Vitamin D (VD) exerts a wide variety of biological actions in addition to its well-known roles in calcium homeostasis. Nutritional VD deficiency induces rachitic abnormalities in growing children and osteomalacia in adults, and it has been proposed to underlie the onset and development of multiple non-communicable chronic diseases. Therefore, the administration of VD or synthetic VD analogues represents a promising therapeutic strategy; indeed, VD and a VD agonist have shown clinical promise in mitigating osteoporosis and symptoms of insufficient calcium intake. However, even though high doses of VD analogues have shown pre-clinical efficacy against several diseases, including cancers, they have not yet had wide-spread clinical success. This difference may be due to limitation of clinical doses in light of the inherent calcemic action of VD. An approach to overcome this problem involves the development of VD analogues with lower calcemic activity, which could be administered in high doses to attenuate the onset and progress of disease. In a similar strategy, selective estrogen receptor modulators have had success as anti-osteoporosis drugs, and they have shown benefit for other estrogen target organs by serving as partial antagonists or agonists of estrogen receptor α. It is thus conceivable to generate synthetic partial antagonists or agonists for the VD receptor (VDR) that would exert beneficial effects on bone and other VD target organs. In this review, we discuss the molecular basis of the development of such synthetic VDR ligands from the viewpoint of roles of VDR in gene regulation.
참고문헌 (50)
- Morris HA, "Autocrine and paracrine actions of vitamin d", Clin Biochem Rev, 31, pp.129~138 (2010)
- Holick MF, "Vitamin D deficiency : a worldwide problem with health consequences", Am J Clin Nutr, 87, pp.1080s~1086s (2008)[DOI]
- Bouillon R, "Vitamin D and human health : lessons from vitamin D receptor null mice", Endocr Rev, 29, pp.726~776 (2008)[DOI]
- Yoshizawa T, "Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning", Nat Genet, 16, pp.391~396 (1997)[DOI]
- Kitanaka S, "Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets", N Engl J Med, 338, pp.653~661 (1998)[DOI]
- Panda DK, "Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction", Proc Natl Acad Sci USA, 98, pp.7498~7503 (2001)[DOI]
- Zhang Y, "Association between vitamin D supplementation and mortality : systematic review and meta-analysis", BMJ, 366, pp.l4673~ (2019)[DOI]
- Bouillon R, "The health effects of vitamin D supplementation : evidence from human studies", Nat Rev Endocrinol, 18, pp.96~110 (2022)[DOI]
- Nielsen OH, "Managing vitamin D deficiency in inflammatory bowel disease", Frontline Gastroenterol, 10, pp.394~400 (2019)[DOI]
- Samuel S, "Vitamin D's role in cell proliferation and differentiation", Nutr Rev, 66, pp.S116~S124 (2008)[DOI]
- Miyamoto H, "Determination of a serum 25-hydroxyvitamin D reference ranges in Japanese adults using fully automated liquid chromatography-tandem mass spectrometry", J Nutr, 153, pp.1253~1264 (2023)[DOI]
- Greten FR, "Inflammation and cancer: triggers, mechanisms, and consequences", Immunity, 51, pp.27~41 (2019)[DOI]
- Furman D, "Chronic inflammation in the etiology of disease across the life span", Nat Med, 25, pp.1822~1832 (2019)[DOI]
- Forno E, "Effect of vitamin D3 supplementation on severe asthma exacerbations in children with asthma and low vitamin D levels : the VDKA randomized clinical trial", JAMA, 324, pp.752~760 (2020)[DOI]
- Harrison SR, "Vitamin D, autoimmune disease and rheumatoid arthritis", Calcif Tissue Int, 106, pp.58~75 (2020)[DOI]
- Sherman MH, "Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy", Cell, 159, pp.80~93 (2014)[DOI]
- Wei Z, "Vitamin D switches BAF complexes to protect β cells", Cell, 173, pp.1135~1149.e15 (2018)[DOI]
- Leyssens C, "The future of vitamin D analogs", Front Physiol, 5, pp.122~ (2014)[DOI]
- Harrison JS, "Clinical experience using vitamin d and analogs in the treatment of myelodysplasia and acute myeloid leukemia : a review of the literature", Leuk Res Treatment, 2012, pp.125814~ (2012)[DOI]
- Manson JE, "Vitamin D supplements and prevention of cancer and cardiovascular disease", N Engl J Med, 380, pp.33~44 (2019)[DOI]
- Yin K, "Vitamin D and inflammatory diseases", J Inflamm Res, 7, pp.69~87 (2014)[DOI]
- Chen Y, "Vitamin D receptor inhibits nuclear factor κB activation by interacting with IκB kinase β protein", J Biol Chem, 288, pp.19450~19458 (2013)[DOI]
- Christakos S, "Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects", Physiol Rev, 96, pp.365~408 (2016)[DOI]
- Schlingmann KP, "Mutations in CYP24A1 and idiopathic infantile hypercalcemia", N Engl J Med, 365, pp.410~421 (2011)[DOI]
- Tebben PJ, "Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy", J Clin Endocrinol Metab, 97, pp.E423~E427 (2012)[DOI]
- Haussler MR, "The nuclear vitamin D receptor : biological and molecular regulatory properties revealed", J Bone Miner Res, 13, pp.325~349 (1998)[DOI]
- Shun Sawatsubashi, "The Function of the Vitamin D Receptor and a Possible Role of Enhancer RNA in Epigenomic Regulation of Target Genes: Implications for Bone Metabolism", 대한골대사학회지, 26(1), pp.3~12 (2019), 대한골대사학회
- Takeyama K, "25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis", Science, 277, pp.1827~1830 (1997)[DOI]
- Meyer MB, "A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3", J Biol Chem, 285, pp.15599~15610 (2010)[DOI]
- Glass CK, "The coregulator exchange in transcriptional functions of nuclear receptors", Genes Dev, 14, pp.121~141 (2000)
- Kato S, "Nuclear receptor coregulators merge transcriptional coregulation with epigenetic regulation", Trends Biochem Sci, 36, pp.272~281 (2011)[DOI]
- Greer EL, "Histone methylation: a dynamic mark in health, disease and inheritance", Nat Rev Genet, 13, pp.343~357 (2012)[DOI]
- Rosenfeld MG, "Sensors and signals : a coactivator", corepressor, Genes Dev, pp.2006, 20[DOI]
- Chen T, "Chromatin modifiers and remodellers : regulators of cellular differentiation", Nat Rev Genet, 15, pp.93~106 (2014)[DOI]
- Sawada T, "The epigenetic function of androgen receptor in prostate cancer progression", Front Cell Dev Biol, 11, pp.1083486~ (2023)[DOI]
- Matsumoto T, "Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients(e-GLORIA)", J Bone Miner Metab, 38, pp.522~532 (2020)[DOI]
- Matsumoto T, "A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures-a randomized, active comparator, double-blind study", Bone, 49, pp.605~612 (2011)[DOI]
- Rovito D, "Cytosolic sequestration of the vitamin D receptor as a therapeutic option for vitamin D-induced hypercalcemia", Nat Commun, 11, pp.6249~ (2020)[DOI]
- Riggs BL, "Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice", N Engl J Med, 348, pp.618~629 (2003)[DOI]
- Jordan VC, "Selective estrogen receptor modulation : concept and consequences in cancer", Cancer Cell, 5, pp.207~213 (2004)[DOI]
- McDonnell DP, "The molecular mechanisms underlying the pharmacological actions of ER modulators : implications for new drug discovery in breast cancer", Curr Opin Pharmacol, 10, pp.620~628 (2010)[DOI]
- Berry M, "Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen", EMBO J, 9, pp.2811~2818 (1990)[DOI]
- Negro-Vilar A, "Selective androgen receptor modulators(SARMs) : a novel approach to androgen therapy for the new millennium", J Clin Endocrinol Metab, 84, pp.3459~3462 (1999)[DOI]
- Solomon ZJ, "Selective androgen receptor modulators : current knowledge and clinical applications", Sex Med Rev, 7, pp.84~94 (2019)[DOI]
- Nettles KW, "Allosteric control of ligand selectivity between estrogen receptors alpha and beta : Implications for other nuclear receptors", Mol Cell, 13, pp.317~327 (2004)[DOI]
- Nadal M, "Structure of the homodimeric androgen receptor ligand-binding domain", Nat Commun, 8, pp.14388~ (2017)[DOI]
- Brzozowski AM, "Molecular basis of agonism and antagonism in the oestrogen receptor", Nature, 389, pp.753~758 (1997)[DOI]
- Nagpal S, "Promoter context-and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors", Cell, 70, pp.1007~1019 (1992)[DOI]
- Lupien M, "FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription", Cell, 132, pp.958~970 (2008)[DOI]
- Sawada T, "Antagonistic action of a synthetic androgen ligand mediated by chromatin remodeling in a human prostate cancer cell line", Biochem Biophys Res Commun, 612, pp.110~118 (2022)[DOI]